Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049751 · ClinicalTrials.gov registry record · Phase 3
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
A Phase 3 study of Rheumatoid Arthritis, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
- 20
- Study locations
NCT00049751: Completed Phase 3 study of Rheumatoid Arthritis, sponsored by Abbott.
NCT00049751 is a Phase 3 study of Rheumatoid Arthritis that has completed, run by Abbott. The registered enrollment target is 3,000 participants, below the 4,675-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049751, a Phase 3 study of Rheumatoid Arthritis, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).
Conditions Studied
Interventions
- DRUG Adalimumab
Study Locations (20)
California
- Desert Valley Medical - Apple Valley
- Kenneth Hsu, MD, Inc. - Bakersfield
- Rheumatology Clinic - Los Angeles
- Michael Harrington, MD - Napa
- Midori Jane Nishio, MD - Walnut Creek
- Naveen Raja, MD - Whittier
Illinois
- Loyola University Medical Center - Maywood
- West Suburban Health Care - Oak Park
- OSF Medical Group -Rheumatology - Peoria
- Rockford Clinic, Clinical Research Department - Rockton
- Pain Therapy Center - Schaumburg
Florida
- Norman Gaylis, MD - Aventura
- Mike Schweitz, MD - West Palm Beach
- Maurice McCarthy, MD - Winter Haven
Connecticut
- Division of Rheumatic Diseases/University of CT Health Center - Farmington
- New Haven Medical Group, PC - New Haven
Idaho
- Intermountain Orthopedics - Boise
- Institute of Arthritis Research - Idaho Falls
Alabama
- Thomas McGee, MD - Mobile
Colorado
- Mountain Rheumatology - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2002-09 |
| Phase | Phase 3 |
What the finished NCT00049751 record still lists
NCT00049751 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, below the 4,675-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab is the first listed.
NCT00049751 names 20 study sites across 7 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT00049751 about?
NCT00049751 is a clinical study titled "Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis". The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).
What is the current status of trial NCT00049751?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants. The study started on 2002-09.
What conditions does trial NCT00049751 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00049751?
The interventions under investigation include: Adalimumab (DRUG).
Who is sponsoring clinical trial NCT00049751?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00049751 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00049751's enrollment target sits among peer trials
3,000 9th of 197 higher than 189 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia